Cancer-Associated Systemic Syndrome (CASS): The mechanism of VEGF in tumor-bearing mice

Chinese Journal of Lung Cancer

Volumn 12, Issue 4, 2009, Pages 283-288

  Chen, Fang ^a   Xue, Yuan ^b   Cao, Yihai ^b   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer associated systemic syndrome; Neoplasms; Vascular endothelial growth factor A

Indexed keywords

HEMOGLOBIN; VASCULOTROPIN;

ADRENAL GLAND; ADVANCED CANCER; ANEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD LEVEL; BLOOD VESSEL; BONE MARROW; CANCER PATIENT; CELL COUNT; CELL TRANSPLANTATION; CONFOCAL MICROSCOPY; DISEASE COURSE; ERYTHROCYTE; FIBROSARCOMA; HEPATOSPLENOMEGALY; HISTOLOGY; INTROSPECTION; LIVER; MICROSCOPE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; SURVIVAL; SURVIVAL RATE; SYSTEMIC DISEASE; TUMOR CELL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 66749148962     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.04.05     Document Type: Article

References (18)

1. Bozzetti F. Continuing: Biology of cachexia. J Natl Cancer Inst, 1999, 91(12): 1765-1770.
2. MacDonald N, Easson AM, Mazurak VC, et al. Understanding and managing cancer cachexia. J Am Coll Surg, 2003, 197(1): 143-161.
3. Stewart GD, Skipworth RJ, Fearon KC. Cancer cachexia and fatigue. Clin Med, 2006, 6(2): 140-143.
4. Dewys W. Management of cancer cachexia. Semin Oncol, 1985, 12(4): 452-460. (Pubitemid 16171830)
5. Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract, 2005, 20(4): 369-376.
6. Costelli P, Llovera M, Carbo N, et al. Interleukin-1 receptor antagonist (IL-Iα) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett, 1995, 95(1-2): 33-38.
7. Socher SH, Martinez D, Craig JB, et al. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst, 1988, 50: 595-598.
8. Matthys PL, Dijkmans R, Proost P, et al. Severe cachexia in mice inoculated with interferon- γ producing tumor cells. Int J Cancer, 1991, 49(1): 77-82.
9. Kayacan O, Karnak D, Beder S, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol, 2006, 29(4): 328-335.
10. Cao Y. Opinion: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer, 2005, 5(9): 735-743. (Pubitemid 41486366)
11. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PIGF-1/VEGF heterodimers. Cancer Cell, 2002, 1(1): 99-108.
12. Cao R, Björndahl MA, Gallego MI, et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood, 2006, 107(9): 3531-3536.
13. Yuan Xue, Piotr Religa, Renhai Cao, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A, 2008, 105(47): 18513-18518.
14. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage, 2007, 34(1): 941-944.
15. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in an anemic cancer patients. Haematologica, 2002, 87(11): 1209-1221. (Pubitemid 35397781)
16. Curt GA, Breitbart W, Celia D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. The Oncologist, 2005, 5: 353-360.
17. Jacobsen PB, Thors CL, Cawley M, et al. Relation of decline in hemoglobin to cognitive functioning and fatigue during chemotherapy treatment. Proc Am Soc Clin Oncol, 21: 2002 (abstr 1542).
18. Caro JJ, Salas M, Ward A, et al. Anemia as all independent prognostic factor for survival in patients with cancer: a systemic quantitative review. Cancer, 2001, 91(2): 2214-2221. (Pubitemid 32552805)